575 related articles for article (PubMed ID: 9287233)
1. Pathogenesis and treatment of sickle cell disease.
Bunn HF
N Engl J Med; 1997 Sep; 337(11):762-9. PubMed ID: 9287233
[No Abstract] [Full Text] [Related]
2. Management of sickle cell disease.
Steinberg MH
N Engl J Med; 1999 Apr; 340(13):1021-30. PubMed ID: 10099145
[No Abstract] [Full Text] [Related]
3. Hydroxyurea for sickle cell anemia.
Naina HV; Harris S
N Engl J Med; 2008 Jul; 359(1):98; author reply 98-9. PubMed ID: 18596283
[No Abstract] [Full Text] [Related]
4. Sickle cell disease: What all PAs should know.
Kayinqo G
JAAPA; 2012 Sep; 25(9):19-20. PubMed ID: 22991882
[No Abstract] [Full Text] [Related]
5. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
Okam MM; Ebert BL
Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210
[TBL] [Abstract][Full Text] [Related]
6. Sickle cell paths converge on hydroxyurea.
Platt OS
Nat Med; 1995 Apr; 1(4):307-8. PubMed ID: 7585059
[No Abstract] [Full Text] [Related]
7. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
Anderson N
Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291
[TBL] [Abstract][Full Text] [Related]
8. Pathophysiologically based drug treatment of sickle cell disease.
Steinberg MH
Trends Pharmacol Sci; 2006 Apr; 27(4):204-10. PubMed ID: 16530854
[TBL] [Abstract][Full Text] [Related]
9. Should we still be focused on red cell hemoglobin F as the principal explanation for the salutary effect of hydroxyurea in sickle cell disease?
Segel GB; Simon W; Lichtman MA
Pediatr Blood Cancer; 2011 Jul; 57(1):8-9. PubMed ID: 21480473
[No Abstract] [Full Text] [Related]
10. New treatments of sickle cell disease.
Embury SH
West J Med; 1996 May; 164(5):444. PubMed ID: 8686307
[No Abstract] [Full Text] [Related]
11. Hydroxyurea for the treatment of sickle cell anemia.
Platt OS
N Engl J Med; 2008 Mar; 358(13):1362-9. PubMed ID: 18367739
[No Abstract] [Full Text] [Related]
12. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
[TBL] [Abstract][Full Text] [Related]
13. Hydroxycarbamide for sickle-cell anaemia in infancy.
Weatherall DJ
Lancet; 2011 May; 377(9778):1628-30. PubMed ID: 21571132
[No Abstract] [Full Text] [Related]
14. Overview of pathophysiology and rationale for treatment of sickle cell anemia.
Rodgers GP
Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea, sickle cell disease and renal transplantation.
Allen A; Scoble J; Snowden S; Hambley H; Bellingham A
Nephron; 1997; 75(1):106-7. PubMed ID: 9031282
[No Abstract] [Full Text] [Related]
16. Sickle cell patients find a brand New World.
Noonan SS
N J Med; 1999 Aug; 96(8):23-5. PubMed ID: 10457727
[TBL] [Abstract][Full Text] [Related]
17. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
Vicari P; Barretto de Mello A; Figueiredo MS
Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
[TBL] [Abstract][Full Text] [Related]
18. Principles and indications of chronic transfusion therapy for children with sickle cell disease.
Ware R
Clin Adv Hematol Oncol; 2007 Sep; 5(9):686-8. PubMed ID: 17982409
[No Abstract] [Full Text] [Related]
19. Atrial septal defect closure on cardiopulmonary bypass in a sickle cell anemia: role of hydroxyurea and partial exchange transfusion.
Gosavi KS; Dash SK; Shah BN; Upasani CB
Ann Card Anaesth; 2010; 13(2):145-7. PubMed ID: 20442545
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.
Pearson HA
Adv Pediatr; 1996; 43():309-34. PubMed ID: 8794181
[No Abstract] [Full Text] [Related]
[Next] [New Search]
